Form 4: Catalyst Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, acquired stock options and restricted stock units on November 21, 2024.

Summary

• Gary Ingenito, the Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals, acquired 125,696 stock options and 15,360 restricted stock units on November 21, 2024.
• The stock options have an exercise price of $21.12 and vest in three equal tranches on November 21, 2025, 2026, and 2027.
• Each restricted stock unit represents a contingent right to receive one share of Catalyst Pharmaceuticals common stock upon vesting.
• Following these transactions, Mr. Ingenito directly owns 1,038,271 shares of common stock and 1,053,631 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive as it aligns executive interests with company performance. There are no negative implications.

Positives

• The acquisition of stock options and restricted stock units by a key executive suggests confidence in the company's future performance.
• The vesting schedule of the options and restricted stock units aligns the executive's interests with the long-term success of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of executive compensation in the pharmaceutical industry.
• The vesting schedule of the options and restricted stock units is typical for such grants, aligning executive interests with long-term company performance.
• The number of options and restricted stock units granted is within the range of what is seen for executives at similar companies.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a key executive may be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, restricted stock units, executive compensation, insider trading, Gary Ingenito, CPRX